Person:
Hudson, Margo

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Hudson

First Name

Margo

Name

Hudson, Margo
Author's Publications: search.filters.isAuthorOfPublication.ddb7e33f-d187-48f4-8100-07c229184616

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Design of a pharmacogenetic Resource for Type 2 Diabetes
    (Public Library of Science, 2015) Walford, Geoffrey A.; Colomo, Natalia; Todd, Jennifer; Billings, Liana K.; Fernandez, Marlene; Chamarthi, Bindu; Warner, A. Sofia; Davis, Jaclyn; Littleton, Katherine R.; Hernandez, Alicia M.; Fanelli, Rebecca R.; Lanier, Amelia; Barbato, Corinne; Ackerman, Rachel J.; Khan, Sabina Q.; Bui, Rosa; Garber, Laurel; Stolerman, Elliot S.; Moore, Allan F.; Huang, Chunmei; Kaur, Varinderpal; Harden, Maegan; Taylor, Andrew; Chen, Ling; Manning, Alisa; Huang, Paul; Wexler, Deborah; McCarthy, Rita M.; Lo, Janet; Thomas, Melissa K.; Grant, Richard W.; Goldfine, Allison B.; Hudson, Margo; Florez, Jose
    Objective: Genome-wide association studies have uncovered a large number of genetic variants associated with type 2 diabetes or related phenotypes. In many cases the causal gene or polymorphism has not been identified, and its impact on response to anti-hyperglycemic medications is unknown. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH, NCT01762046) is a novel resource of genetic and biochemical data following glipizide and metformin administration. We describe recruitment, enrollment, and phenotyping procedures and preliminary results for the first 668 of our planned 1,000 participants enriched for individuals at risk of requiring anti-diabetic therapy in the future. Methods: All individuals are challenged with 5 mg glipizide × 1; twice daily 500 mg metformin × 2 days; and 75-g oral glucose tolerance test following metformin. Genetic variants associated with glycemic traits and blood glucose, insulin, and other hormones at baseline and following each intervention are measured. Results: Approximately 50% of the cohort is female and 30% belong to an ethnic minority group. Following glipizide administration, peak insulin occurred at 60 minutes and trough glucose at 120 minutes. Thirty percent of participants experienced non-severe symptomatic hypoglycemia and required rescue with oral glucose. Following metformin administration, fasting glucose and insulin were reduced. Common genetic variants were associated with fasting glucose levels. Conclusions: SUGAR-MGH represents a viable pharmacogenetic resource which, when completed, will serve to characterize genetic influences on pharmacological perturbations, and help establish the functional relevance of newly discovered genetic loci to therapy of type 2 diabetes. Trial Registration ClinicalTrials.gov NCT01762046
  • Thumbnail Image
    Publication
    Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards
    (Endocrine Society, 2017) Gupta, Tina; Hudson, Margo
    Hyperglycemia is a common issue affecting inpatient care. Although this is in part because of the higher rate of hospitalization among patients with preexisting diabetes, multiple factors complicate inpatient glucose management, including acute stress from illness or surgery, erratic dietary intake, and contribution of medications. It has been repeatedly demonstrated that poorly controlled blood glucose levels are associated with negative clinical outcomes, such as increased mortality, higher rate of surgical complications, and longer length of hospital stay. Given these concerns, there has been extensive study of the optimal strategy for management of glucose levels, with the bulk of existing literature focusing on insulin therapy in the intensive care unit setting. This review shifts the focus to the general adult medical and surgical wards, using clinical guidelines and sentinel studies to describe the scientific basis behind the current basal-bolus insulin-based approach to blood sugar management among noncritically ill inpatients. Patient-centered clinical trials looking at alternative dosing regimens and insulin analog and noninsulin agents, such as glucagon-like peptide-1 agonist therapies, introduce safe and effective options in the management of inpatient hyperglycemia. Data from these studies reveal that these approaches are of comparable safety and efficacy to the traditional basal-bolus insulin regimen, and may offer additional benefit in terms of less monitoring requirements and lower rates of hypoglycemia. Although existing data are encouraging, outcome studies will be needed to better establish the clinical impact of these more recently proposed approaches in an effort to broaden and improve current clinical practices in inpatient diabetes care.